CJC-1295 No DAC Pre-Research Checklist

Before a single vial enters your inventory, five things need to be confirmed in writing: the identity of the molecule (No DAC is not the same compound as the DAC version), purity established by HPLC on a lot-specific certificate of analysis, the full scope of the contamination panel behind that certificate, the storage and shipping conditions the supplier commits to, and the commercial terms — pricing structure, minimums, fulfillment, and what happens when a lot is disputed. Everything else is negotiable. Those five are not, because each one is a point where a catalog listing can quietly diverge from what arrives on your dock.

This is written for the business buyer — the med spa owner, clinic operator, telehealth founder, or reseller building a research catalog. All compounds discussed here are research use only and are not FDA-approved drugs. Nothing below is legal advice.

Why this particular compound demands extra sourcing scrutiny

CJC-1295 exists in two forms that share a name. The version with DAC carries a drug affinity complex, a chemical modification intended to extend how long the peptide persists in circulation in study models. The version without DAC — often catalogued as modified GRF (1-29) — lacks that modification and behaves very differently in research settings. Published peptide chemistry literature suggests the two produce meaningfully different pharmacokinetic profiles precisely because of that structural difference. They are not interchangeable, and a study designed around one is not a study about the other.

That naming overlap is the sourcing problem in a sentence. A catalog can list "CJC-1295" with no qualifier. A certificate of analysis can be uploaded that belongs to a different lot, or to the DAC variant, and unless the reader checks the reported mass against the expected molecular weight, the mismatch is invisible. A second wrinkle: research literature frequently studies growth hormone secretagogue compounds alongside one another, so a catalog may cross-reference related items. Cross-referencing is fine. Substituting is not. Your verification has to name the molecule, not the marketing term.

What a certificate of analysis has to actually show

Most purity disputes come down to one question: is this document about the vial I received, or about a vial that existed once? A representative or "typical" COA describes a product line. A lot-specific COA describes the material in your hands. Only one of those is evidence.

Ask for a document that carries a lot or batch number matching the vial label, a test date, the name of the laboratory that ran the work, and the analytical method. On the purity side, an HPLC chromatogram with a stated purity percentage is the baseline — not a bare number typed onto a letterhead, but the trace itself, so you can see whether the main peak is clean or shouldered by co-eluting impurities.

Purity and identity are separate questions, and this is where a lot of buyers stop one step short. HPLC tells you what proportion of the material is a single species. It does not tell you which species. Mass spectrometry answers identity by reporting observed mass against the expected molecular weight for the specific sequence. For a compound with a near-twin in the same catalog, identity confirmation is the single most valuable line on the page.

Contamination panels: scope matters more than the headline number

A supplier advertising "tested" is telling you almost nothing until you know how many assays and which ones. Ask for the panel by name. Categories commonly requested across research peptide sourcing include appearance and solubility, moisture or water content, counterion and residual acetate content, residual solvents, heavy metals, microbial or bioburden screening, and bacterial endotoxin. A supplier that runs a multi-assay panel should be able to list what it covers without hesitating, and the report should show results per assay rather than a single pass/fail stamp.

Where testing occurs also matters. Material can be tested at the manufacturer and never re-tested after it changes hands, or it can be tested again per batch at the point of distribution. The second is more meaningful to you, because that is the material you are receiving. Ask which one you are being shown.

Finally, ask how you get the document. If a COA is available only on request, or sold as an add-on, or emailed as a flattened image with no lab identifiers, you are being asked to trust rather than verify. Publicly posted, lot-referenced lab results let you check the work before you commit a purchase order — and let you show the same evidence to your own reviewers.

The verification table to run before any order

Handling, storage and the records you keep on your side

Verification does not end when the box arrives; it shifts to you. Research peptides in this class ship as lyophilized powder, and suppliers generally specify refrigerated or frozen storage with protection from light and moisture. Do not improvise this — follow the condition your supplier states in writing, and get it in writing before you order rather than after a shipment sits on a receiving desk.

Build a receiving log that captures, per shipment: lot number, quantity, arrival date, packaging condition on arrival, and whether cold-chain materials were still effective. Attach the lot-specific COA to that record. This is unglamorous and it is the difference between a supplier conversation that resolves in an afternoon and one that becomes your word against theirs. If you carry multiple secretagogue-class compounds, keep lot records segregated by molecule rather than by catalog category, because that is the level at which a question will eventually be asked.

One boundary worth stating plainly to your own staff: research materials are not veterinary products any more than they are human therapeutics. If a question about animal use ever comes up in your business, route it to a licensed veterinarian rather than answering it in-house. The same discipline applies to every other downstream question — you stock and document; you do not advise.

Compliance questions to put in front of counsel, not answer yourself

This section is informational and is not legal advice. The point is not to tell you what the rules are — it is to tell you which questions are worth paying a professional to resolve before you build a catalog around a compound.

Ask your attorney and, where applicable, your state board: How must research-use-only materials be labeled and stored in a business like mine? What restrictions apply to resale, and do they change if I repackage or relabel? What claims may or may not appear in my marketing, on my site, and in materials my staff hand out? What recordkeeping do I need to be able to produce if asked? Does my business license, or my professional license, interact with any of this? How should I document that a product was sold for research purposes?

Regulatory treatment in this space varies, interpretations shift, and requirements differ by jurisdiction and by business type. Anyone who answers those questions for you in a blog post — including a supplier — is guessing on your behalf. Get the answers from someone who carries professional responsibility for them, and get them before inventory arrives rather than after.

Supplier terms that decide whether lot two matches lot one

A good first order proves nothing. Consistency is the actual product. Before committing, establish how pricing is structured across volume tiers and whether those tiers are disclosed up front or revealed only after you apply — opaque pricing is common in this industry and it makes forecasting impossible. Establish minimums in writing. Establish the fulfillment window and whether stock is held domestically or drop-shipped from overseas, because that difference drives both timing and customs exposure.

Then establish the failure path. If a lot arrives damaged, or the COA does not match the vial, or an assay result looks wrong — who reviews it, what evidence do they want, and what remedy exists? Suppliers who have thought about this answer quickly. Suppliers who have not will improvise, and you will be the one absorbing the cost.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around the verification points above rather than around volume promises. Catalog compounds are supplied at 99%+ HPLC purity, with 7-panel batch testing applied per batch rather than inherited from an upstream manufacturer's paperwork. Certificates of analysis are publicly verifiable — a prospective partner can pull the lab results and check them independently before applying, which is the opposite of the request-only or pay-per-COA practice found elsewhere in the sector. Fulfillment runs from US-based stock, with the program's stated shipping window of 5–7 days. The wholesale application itself is a 3-step process rather than an extended qualification gauntlet.

The compound discussed here is listed as CJC-1295 No DAC 10mg — named by variant, not by the ambiguous shorthand — and sits alongside related secretagogue-class items such as Ipamorelin 10mg and Tesamorelin 10mg in the research catalog. All items are research use only and are not sold for human or veterinary consumption.

If you have run the checklist, resolved your compliance questions with counsel, and want a supplier whose lab documentation you can audit before you buy rather than after, the Wholesale Partner Program application at Real Peptides is the next step — the review process is short, and pricing tiers are disclosed to approved partners rather than hidden behind a deposit.

Related research categories are organized on the Real Peptides site under Growth Factor & Tissue Signaling Research and the broader Popular Peptides collection, with lot-specific COAs accessible from each product page for independent verification.